Satellos Bioscience Inc.: Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures

Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Christina Cameron ,Ryan Mitchell ,Michael Rudnicki ,Geoff Mackay ,Frank Gleeson ,William Jarosz ,Satellos Bioscience Inc ,Company The Debentures ,Company Board ,Venture Exchange ,Regulatory Services Provider ,Communications At Satellos Bioscience Inc ,Newsfile Corp ,Business Development ,Each Unit ,Board Chair ,Multilateral Instrument ,Minority Security Holders ,Special Transactions ,Maturity Date ,Closing Date ,Bonus Shares ,Satellos Bioscience ,Diese Gold Aktie ,Sichern Sie ,Satellos ,Ioscience ,Nnounces ,Closing ,Reviously ,Nnounced ,Rokered ,Offering ,Billion ,Insecured ,Convertible ,Debentures ,